Objectives: To determine whether the addition of metronomic chemotherapy improved outcome for dogs with splenic haemangiosarcoma treated with splenectomy and adjuvant maximum tolerated dose chemotherapy.
INTRODUCTION
Haemangiosarcoma (HSA) is a highly malignant neoplasm of vascular endothelial cell origin (Prymak et al. 1988) . HSA can affect any tissue in the body, but the spleen is the most common site of tumour development, accounting for 50 to 65% of all cases of canine HSA (Schultheiss 2004 ). Other common sites that HSA can affect include the subcutaneous tissues (13 to 17%) (Bulakowski et al. 2008) , liver (9%), right atrium (3 to 25%) (De Madron et al. 1987) and, rarely, bones (including the proximal humerus, femur, ribs and vertebrae) (Bingel et al. 1974) .
Clinical signs associated with visceral HSA include lethargy, weakness, vomiting, diarrhoea, inappetence, acute collapse and death secondary to hypovolamia from internal haemorrhage. The most common sites of metastasis include the liver, mesentery, omentum and lungs (Brown et al. 1985 , Waters et al. 1988 . In the majority of cases metastasis has usually already occurred at the time of diagnosis and dogs that undergo surgery to resect the primary tumour typically succumb to metastatic disease within a short period of time usually due to invasion of vital organs or acute blood loss.
The mainstay of therapy for splenic HSA consists of surgery (splenectomy) followed by chemotherapy. Reported median survival times with splenectomy alone range from 19 to 86 days (Brown et al. 1985 , Prymak et al. 1988 , Wood et al. 1998 . Doxorubicin-based protocols have historically been used as an adjuvant therapy and have been shown to modestly improve survival times to a median of 141 to 179 days (Hammer et al. 1991 , Sorenmo et al. 1993 , Ogilvie et al. 1996 . Epirubicin has also shown similar efficacy compared to doxorubicin in the adjuvant treatment of splenic HSA (Kim et al. 2007) .
Despite the improvement in survival time with the addition of chemotherapy, overall longevity of these patients remains disappointing. Metronomic chemotherapy (MC) refers to using low doses of cytotoxic chemotherapy on a continuous basis with the goal of altering the tumour microenvironment rather than targeting the tumour itself. MC is thought to inhibit tumour angiogenesis (Kerbel & Kamen 2004) , modulate immune cells (Mitchell et al. 2012) , and reduce the tumour stem cell population by diminishing the population and efficacy of T-regulatory cells (Madondo et al. 2016 , Gaspar et al. 2017 . A study found that splenectomised dogs with stage II HSA treated with adjuvant doxorubicin had comparable survival times to those treated with splenectomy and a metronomic protocol which consisted of low-dose cyclophosphamide, etoposide and piroxicam (Lana et al. 2007) . Another study found dogs with HSA treated with a metronomic protocol consisting of cyclophosphamide, a NSAID (non-steroidal anti-inflammatory drug), ±thalidomide after maximum tolerated dose (MTD) doxorubicin-based chemotherapy had improved median survival times (not reached versus 168 days) and time to metastasis (not reached versus 150 days) (Finotello et al. 2016) .
The goal of this study was to compare the progression free survival (PFS) and overall survival time (OST) of dogs with splenic HSA treated with splenectomy and a MTD anthracycline-based protocol to dogs that received a MC protocol following splenectomy and MTD anthracycline-based protocol.
MATERIALS AND METHODS

Eligibility criteria
The database from the New England Veterinary Oncology Group (NEVOG) in Waltham, MA, USA was reviewed from 2003 to 2015. Dogs with a histologically confirmed diagnosis of splenic HSA confined to the abdominal cavity that were treated with splenectomy plus MTD chemotherapy with or without MC were included in our study. Exclusion criteria included dogs with HSA in non-splenic locations, dogs treated with less than four cycles of MTD chemotherapy, dogs that did not start MTD chemotherapy within 28 days of surgery, dogs with diagnosed pulmonary metastasis at the time of diagnosis and dogs treated with non-anthracycline-based MTD chemotherapy protocols.
Data collected from patients included the following: weight, age, breed, gender, neuter status, stage at the time of diagnosis, imaging performed (thoracic radiographs and/or abdominal radiographs, abdominal and/or cardiac ultrasound when available) and histopathology results. Dogs were staged according to the World Health Organisations guidelines: stage I disease is confined to the spleen (non-ruptured), stage II confined to the spleen and haemoabdomen (±lymph node involvement but no distant metastasis) and stage III is metastatic disease to a distant site (Owen 1980) . Dogs with suspected or confirmed abdominal visceral metastasis were included in this study. Metastases were identified either at time of surgery by biopsy, thoracic radiographs, abdominal ultrasound and/or echocardiography. When re-staging was performed using radiography and/or abdominal/ thoracic ultrasound, any new suspicious lesions (cavitated abdominal masses, actively bleeding masses, lytic bone lesions, cardiac masses and/or pulmonary nodules/infiltrate) were assumed to be metastatic disease. Metastatic disease was not confirmed histologically in all dogs suspected to have metastasis. One dog in the splenectomy and MTD chemotherapy alone group (Group 1), and none of the dogs in the splenectomy and MTD+MC (Group 2) had histopathologically confirmed metastatic disease during re-staging.
MTD chemotherapy information collected included time between splenectomy and start of MTD chemotherapy, chemotherapeutic agent(s) administered, dose administered, total number of cycles, toxicity and need for dose reductions/delays. MC information included time between completion of MTD chemotherapy and starting MC chemotherapy and dosage administered. Additional medications (e.g. NSAID and doxycycline use) were noted if mentioned in the record but, due to the retrospective nature of this study, not all records explicitly stated their use.
Treatment protocol Dogs in Group 1 received a splenectomy followed by MTD anthracycline-based chemotherapy (Table 1) . Dogs were further evaluated based on whether they received MTD cyclophosphamide. Group 1a received MTD anthracycline without MTD cyclophosphamide. Group 1b received MTD anthracycline and MTD cyclophosphamide. Doxorubicin was administered at starting dose of 27 to 30 mg/m 2 for dogs weighing greater than 15 kg, and 0·8 to 1 mg/kg for dogs weighing less than 15 kg. Epirubicin was used in one patient at a dose of 30 mg/m 2 due to unavailability of doxorubicin at that time. All treatments were administered at 3-week intervals. MTD cyclophosphamide was used concurrently with doxorubicin based at the discretion of the attending clinician. If cyclophosphamide was used in conjunction with doxorubicin, it was administered at 200 mg/m 2 and divided over a 4-day period (days 3, 4, 5 and 6 after doxorubicin). Dogs in Group 2 were treated by splenectomy, MTD anthracycline-based chemotherapy, and MC (Table 1) . Dogs were further evaluated based on whether they received MTD cyclophosphamide. Group 2a received MTD anthracycline without MTD cyclophosphamide and MC. Group 2b received MTD anthracycline+MTD cyclophosphamide+MC. Doxorubicin was used at a starting dose of 25 to 30 mg/m 2 for dogs weighing greater than 15 kg, and 1 mg/kg for dogs weighing less than 15 kg. All treatments were administered at 3-week intervals. If cyclophosphamide was used in conjunction with doxorubicin, it was administered at a dose range of 150 to 200 mg/m 2 and divided over a 4-day period (days 3, 4, 5 and 6 after doxorubicin).
MC cyclophosphamide was administered at 12·5 mg/m 2 daily or 25 mg/m 2 every other day. Restaging with thoracic radiographs and/or abdominal ultrasound was planned at 90-day intervals.
Statistical analysis methods
All analyses were performed using SAS V 9·3. Kaplan-Meier survival curves for OST and PFS were constructed by treatments groups, by stage, and the use of MTD cyclophosphamide. Median OST and PFS and 95% confidence intervals were estimated from the Kaplan-Meier survival curves for each strata. Kaplan-Meier survival analysis was also used to estimate median time between starting MC and death.
RESULTS
Group 1 (Splenectomy + MTD chemotherapy) There were a total of 39 dogs included in Group 1. Of these 39 dogs, there were: 11 golden retrievers, nine mixed breed dogs, five Labrador retrievers, two dachshunds, two Scottish terriers, two German shepherd dogs and one of each of boxer, English springer spaniel, standard schnauzer, cocker spaniel, Bernese mountain dog, whippet, bichon frise and Portuguese water dog. There were 23 males (22 neutered and one intact) and 16 females (all spayed). The mean age was 9·3 years old (range 4·2 to 13·9 years old) and the mean weight was 26·2 kg (range 7·0 The mean time from surgery to starting MTD anthracyclinebased chemotherapy was 16·7 days (range 8 to 27 days). Of those 39 dogs, 29 received a combination of doxorubicin and cyclophosphamide while 10 dogs received doxorubicin alone. The mean number of cycles administered was five (range four to six). Thirteen dogs in group 1 required a dose reduction due to toxicity. There were six grade I toxicities (three gastrointestinal and three neutropenia), 10 grade II toxicities (eight gastrointestinal, one neurologic and one neutropenia), one grade III (neutropenia) toxicity and two grade IV (neutropenia) toxicities. One dog was suspected to have sterile haemorrhagic cystitis (SHC) at the fifth cycle of MTD doxorubicin+cyclophosphamide and received the final (sixth cycle) MTD doxorubicin without cyclophosphamide. The patient was later confirmed to have a urinary tract infection making SHC less likely to be the cause of the observed clinical signs.
Group 2 (Splenectomy + MTD chemotherapy+MC)
There were a total of 22 dogs included in Group 2. Of these 22 dogs, there were: five mixed breed dogs, five Labrador retrievers, four golden retrievers, two Belgian shepherds and one of each of German shepherd dog, American Eskimo dog, briard, cocker spaniel, Australian shepherd and bloodhound. There were 10 neutered males and 12 spayed females. Mean age was 9·9 years old (range 7·3 to 14·6 years old) and mean weight was 30·4 kg (range 14·7 to 44·3 kg). According to the WHO staging guideline, there were four dogs with stage I disease, 13 dogs with stage II disease and five dogs with stage III disease.
The mean time from surgery to starting traditional anthracycline-based chemotherapy was 16·1 days (range 8 to 26 days). The mean number of MTD chemotherapy cycles administered was 5·5 (range four to six). Five out of 22 dogs were treated with a combination of MTD doxorubicin and cyclophosphamide while 16 dogs received MTD doxorubicin alone. One dog received a dose of 25 mg/m 2 single agent epirubicin followed by MC. In one dog, doxorubicin and MC were started simultaneously.
Three dogs in Group 2 required a dose reduction due to toxicity during MTD chemotherapy. There were two grade I (lethargy and neutropenia) toxicities, five grade II (gastrointestinal) toxicities and one grade III (neutropenia) toxicity. There were no episodes of SHC. There were no reported toxicities secondary to MC.
The mean time from finishing the MTD anthracycline-based chemotherapy to starting MC was 22·2 days (range 0 to 30 days). All dogs receiving MC were treated with cyclophosphamide. A dose of 12·4 mg/m 2 MC cyclophosphamide was administered at a mean daily (range 8·9 to 25·2 mg/m 2 ). Eighteen out of 22 dogs received 25 mg cyclophosphamide every other day as this was the commercially available product. Four dogs received compounded cyclophosphamide (three administered daily and one every other day). Thirteen dogs received concurrent NSAIDs and five dogs received doxycycline in addition to the metronomic cyclophosphamide. Restaging with thoracic radiographs and/or abdominal ultrasound was performed at a median of every 86 days (Group 1 range 50 to 176 days; group 2 range 29 to 152 days) during and following MTD chemotherapy.
STATISTICAL ANALYSIS
The median PFS and OST for dogs in Group 1 were 165 days [95% confidence interval (95% CI) 140 to 180 days] and 180 days (95% CI 158 to 190 days), respectively (Fig. 1, Table 2) . Similarly, the median PFS and OST for dogs in Group 2 were 185 days (95% CI 152 to 223 days) and 212 days (95% CI 166 to 278 days), respectively (Fig. 1, Table 2 ). The distribution of dogs between stages was also comparable between groups (Table 1 ). In both Group 1 and Group 2, median survival was worse in animals that were treated with MTD cyclophosphamide (Fig. 2 , Table 2 ). There were two dogs (one still alive at time of writing paper and one lost to follow-up) in Group 1 that were censored in the analysis. 
DISCUSSION
Splenic HSA continues to be a devastating disease in dogs because it is locally invasive and carries a high metastatic rate. Outcomes have remained disappointing despite years of research into treatment for this cancer. In this study, the addition of MC to a conventional MTD chemotherapy protocol did not improve OST or PFS in dogs with splenic HSA after splenectomy. The median OST in group 1 (MTD chemotherapy alone) was 180 days while in group 2 (MTD+MC) was 212 days. The median OST in both groups is consistent with previously reported survival data (Hammer et al. 1991 , Ogilvie et al. 1996 for dogs treated with splenectomy and anthracycline-based MTD chemotherapy. While the median OST (which represents the 50% survival point) was lower in Group 1 than Group 2, the Kaplan-Meier survival curves cross after 400 days indicating that Group 1 survival is not consistently lower than Group 2 survival for dogs that live longer than 400 days. This indicates a lack of consistent differences in survival due to the addition of MC to conventional MTD chemotherapy protocol.
In the study performed by Finotello et al. (2016) in which thalidomide was utilised in 70% of the patients along with MC cyclophosphamide and a NSAID, there was improvement in the PFS and OST. Thalidomide has known anti-angiogenic properties (Rebuck & Fish 1998) . Therefore, it is possible that the improved survival times and time to metastasis noted in the MTD chemotherapy-MC group in that study were attributable to thalidomide alone or a synergistic effect of thalidomide and MC. Finotello et al. (2016) also included dogs with non-visceral HSA (i.e. subcutaneous HSA and osseous HSA) which may have contributed to the overall improved survival times found in their study as there are documented survival differences based on the primary tumour location (Ward et al. 1994 , Waters & Cooley 1998 , Garzotto & Berg 2003 .
The study by Lana et al. (2007) included only dogs with splenic HSA. Those dogs received alternating metronomic cyclophosphamide and etoposide along with piroxicam but without an anthracycline. The survival time in that study was significantly longer compared to dogs that had undergone splenectomy alone and similar to dogs that had received anthracycline-based MTD. This may suggest activity of this particular metronomic protocol. Low-dose etoposide has been shown to cause decreased production of vascular endothelial growth factor (VEGF) by tumour cells, decreased endothelial and tumour cell proliferation and inhibited endothelial tube formation (Panigraphy et al. 2010) . Since low-dose etoposide was used as part of this protocol it may have altered (or improved) the overall efficacy of the treatment.
Contrary to previously published data (Lana et al. 2007 , Finotello et al. 2016 no benefit was noted from the addition of MC in our study. Our findings were also similar to Gardner et al. (2015) in which no improvement in disease-free interval or survival time was noted with the addition of a maintenance protocol after completion of doxorubicin with toceranib. One of the targets of toceranib is VEGF which is also a target of MC (Albertsson et al. 2009 ). Similar to the addition of MC, toceranib did not improve outcome, likely indicating that multiple pathways are responsible for disease progression. Recently, a similar study also found no benefit from the addition of metronomic cyclophosphamide for dogs with splenic HSA treated with adjuvant MTD chemotherapy (Matsuyama et al. 2017) .
Studies have investigated alternative tumour microenvironment modulating agents without any proven benefit. Only few dogs in our study received NSAIDs and/or doxycycline to draw meaningful conclusions regarding effects of these drugs. A previous study by Kahn evaluating the use NSAIDs with doxorubicinbased chemotherapy failed to show improved outcome for dogs with splenic HSA (Kahn et al. 2013) . Similarly, Sorenmo et al. (2000) found no difference in outcome for dogs receiving minocycline in addition to a doxorubicin-based protocol.
Notably, the use of cyclophosphamide as part of a MTD protocol led to worse outcome in our study. This is likely due to our small sample size creating a random, spurious, finding. It is also possible that dogs with more aggressive disease may have been selected to receive cyclophosphamide due to clinician or owner bias. Limitations of this study include relatively small sample size in both groups and its retrospective nature. Patients were not randomised to treatment groups so there may have been bias in which patients received MC. Echocardiograms were not routinely performed in all patients which may have caused dogs to be understaged. Not all dogs were re-staged at the same time during their treatment protocols which may have led to variability in PFS.
There is paucity of evidence in the literature regarding the ideal dose of MC agents as well the correct timing of when to start MC. Additionally, there is a lack of information regarding proper biomarkers to assess the efficacy of MC in vivo. These factors make it challenging to determine the most appropriate drugs, dosage and schedule. Eleven of the dogs in our study were dosed below the most recently published (Burton et al. 2011) recommended metronomic dose of 15 mg/m
